149 related articles for article (PubMed ID: 36411628)
1. AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.
Polonio-Alcalá E; Porta R; Ruiz-Martínez S; Vásquez-Dongo C; Relat J; Bosch-Barrera J; Ciurana J; Puig T
Biomed Pharmacother; 2022 Dec; 156():113942. PubMed ID: 36411628
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.
Ali A; Levantini E; Teo JT; Goggi J; Clohessy JG; Wu CS; Chen L; Yang H; Krishnan I; Kocher O; Zhang J; Soo RA; Bhakoo K; Chin TM; Tenen DG
EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29449326
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
6. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
7. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
9. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
Fei SJ; Zhang XC; Dong S; Cheng H; Zhang YF; Huang L; Zhou HY; Xie Z; Chen ZH; Wu YL
PLoS One; 2013; 8(7):e69104. PubMed ID: 23874880
[TBL] [Abstract][Full Text] [Related]
10. Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models.
Polonio-Alcalá E; Palomeras S; Torres-Oteros D; Relat J; Planas M; Feliu L; Ciurana J; Ruiz-Martínez S; Puig T
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32438613
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
12. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
13.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
14. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
15. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
[TBL] [Abstract][Full Text] [Related]
16. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
17. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
18. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
20. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]